Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
Weight gain is a serious, common side effect of many antipsychotic medications. On average,
the highest amounts of weight gain are found to occur in people taking clozaril and
olanzapine, but with significant weight gain occuring in those on the other atypical
antipsychotics as well.
We, the researchers at the University of North Carolina, propose an open-label observational,
pilot study of the changes in weight, BMI, body composition, and lipids, glucose, insulin and
other metabolic parameters occurring in subjects as they switch from treatment with
olanzapine, risperidone or quetiapine to aripiprazole. This medication switch will be
determined prior to their entering this study by their treating psychiatrist. We also will
determine resting energy expenditure (REE) and respiratory quotient (RQ) as measured by
metabolic cart to determine if either energy expenditure or the propensity to store energy as
fat may be involved in any changes to weight that are detected. Food intake, hunger, and
physical activity will also be assessed.